Epitalon +1622% BrdU+/NeuN+ adult-born neurones in aged SGZ addresses the stem cell proliferative deficit
For instance, in April 2025, Pfizer, a US-based pharmaceutical company specializing in metabolic and cardiometabolic drug development, provided an update on its oral GLP-1 receptor agonist candidate, danuglipron, following the completion of once-daily formulation studies intended to improve dosing convenience for patients
The RECONNECT trials delivered statistically significant improvements in both desire scores and distress in over 1,200 women, the cardiovascular effects are characterized and manageable, and nausea the dominant side effect diminishes with repeated use
Lp (a) Particles Mold Fibrin-Binding Properties of Apo (a) in Size-Dependent Manner A Study With Different-Length Recombinant Apo (a), Native Lp (a) and Monoclonal Antibody
Which Semaglutide Drugs Will Be Named In Lawsuits